Download PDF
Semin Respir Crit Care Med 2016; 37(02): 230-242
DOI: 10.1055/s-0036-1572559
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mycobacterial Lung Disease Complicating HIV Infection

Michelle K. Haas
1   Denver Metro Tuberculosis Control Program, Denver Public Health, Denver, Colorado
2   Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Aurora, Colorado
,
Charles L. Daley
3   Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, Colorado
4   Department of Medicine, University of Colorado, Denver, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
14 March 2016 (online)

    Permissions and Reprints

Abstract

Mycobacterial infections have caused enormous morbidity and mortality in people living with human immunodeficiency virus (HIV) infection. Of these, the most devastating has been tuberculosis (TB), the leading cause of death among HIV-positive persons globally. TB has killed more people living with HIV than any other infection. Diagnosis of latent TB infection (LTBI) is critical as treatment can prevent emergence of TB disease. Bacteriologic confirmation of TB disease should be sought whenever possible as well as drug susceptibility testing. When detected early, drug susceptible TB is curable. Similar to TB, nontuberculous mycobacteria (NTM) can also produce pulmonary and extrapulmonary infections including disseminated disease that can be fatal. Diagnosis through accurate identification of the pathogenic organism will greatly inform treatment. Depending on the NTM identified, treatment may not be curable. Ultimately, preventive strategies such as initiation of antiretroviral drugs and treatment of LTBI are interventions expected to have significant impacts on control of TB and NTM in the setting of HIV. This chapter will review the impact of pulmonary mycobacterial infections on HIV-positive individuals.

Keywords

mycobacteria - tuberculosis - nontuberculous - human immunodeficiency virus
 

  • References

  • 1 Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2014
  • 2 Ansari NA, Kombe AH, Kenyon TA , et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6 (1) 55-63
    PubMedGoogle Scholar
  • 3 Martinson NA, Karstaedt A, Venter WD , et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21 (15) 2043-2050
    CrossrefPubMedGoogle Scholar
  • 4 Garcia-Jardon M, Bhat VG, Blanco-Blanco E, Stepian A. Postmortem findings in HIV/AIDS patients in a tertiary care hospital in rural South Africa. Trop Doct 2010; 40 (2) 81-84
    CrossrefPubMedGoogle Scholar
  • 5 Wong EB, Omar T, Setlhako GJ , et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS ONE 2012; 7 (10) e47542
    CrossrefPubMedGoogle Scholar
  • 6 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
    CrossrefPubMedGoogle Scholar
  • 7 Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med 2013; 19 (3) 229-237
    CrossrefPubMedGoogle Scholar
  • 8 Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015; 29 (15) 1987-2002
    CrossrefPubMedGoogle Scholar
  • 9 Ford N, Shubber Z, Meintjes G , et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2 (10) e438-e444
    PubMedGoogle Scholar
  • 10 Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191 (2) 150-158
    CrossrefPubMedGoogle Scholar
  • 11 Corbett EL, Watt CJ, Walker N , et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163 (9) 1009-1021
    CrossrefPubMedGoogle Scholar
  • 12 Holmes CB, Wood R, Badri M , et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42 (4) 464-469
    CrossrefPubMedGoogle Scholar
  • 13 Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172 (1) 123-127
    CrossrefPubMedGoogle Scholar
  • 14 Nanoo A, Izu A, Ismail NA , et al. Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004-12: a time series analysis. Lancet Infect Dis 2015; 15 (9) 1066-1076
    CrossrefPubMedGoogle Scholar
  • 15 Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS ONE 2012; 7 (3) e34156
    CrossrefPubMedGoogle Scholar
  • 16 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1) CD000171
    PubMedGoogle Scholar
  • 17 Lawn SD, Wood R, Wilkinson RJ. Changing concepts of “latent tuberculosis infection” in patients living with HIV infection. Clin Dev Immunol 2011; 2011: pii: 980594
    PubMedGoogle Scholar
  • 18 Barry III CE, Boshoff HI, Dartois V , et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7 (12) 845-855
    PubMedGoogle Scholar
  • 19 Crump JA, Ramadhani HO, Morrissey AB , et al. Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55 (2) 242-250
    CrossrefPubMedGoogle Scholar
  • 20 Jacob ST, Pavlinac PB, Nakiyingi L , et al. Mycobacterium tuberculosis bacteremia in a cohort of hiv-infected patients hospitalized with severe sepsis in uganda–high frequency, low clinical suspicion [corrected] and derivation of a clinical prediction score. PLoS ONE 2013; 8 (8) e70305
    CrossrefPubMedGoogle Scholar
  • 21 Bassett IV, Wang B, Chetty S , et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51 (7) 823-829
    CrossrefPubMedGoogle Scholar
  • 22 Cain KP, McCarthy KD, Heilig CM , et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362 (8) 707-716
    CrossrefPubMedGoogle Scholar
  • 23 Varma JK, McCarthy KD, Tasaneeyapan T , et al. Bloodstream infections among HIV-infected outpatients, Southeast Asia. Emerg Infect Dis 2010; 16 (10) 1569-1575
    CrossrefPubMedGoogle Scholar
  • 24 Lawn SD, Kerkhoff AD, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. AIDS 2011; 25 (17) 2190-2191
    PubMedGoogle Scholar
  • 25 Mtei L, Matee M, Herfort O , et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40 (10) 1500-1507
    CrossrefPubMedGoogle Scholar
  • 26 Wood R, Middelkoop K, Myer L , et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175 (1) 87-93
    CrossrefPubMedGoogle Scholar
  • 27 Perenboom RM, Richter C, Swai AB , et al. Clinical features of HIV seropositive and HIV seronegative patients with tuberculous lymphadenitis in Dar es Salaam. Tuber Lung Dis 1995; 76 (5) 401-406
    CrossrefPubMedGoogle Scholar
  • 28 Richter C, Perenboom R, Mtoni I , et al. Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania. Chest 1994; 106 (5) 1471-1475
    CrossrefPubMedGoogle Scholar
  • 29 Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148 (5) 1292-1297
    CrossrefPubMedGoogle Scholar
  • 30 Swindells S, Komarow L, Tripathy S , et al; AIDS Clinical Trials Group 5253 Study Team. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. Int J Tuberc Lung Dis 2013; 17 (4) 532-539
    CrossrefPubMedGoogle Scholar
  • 31 Ngadaya ES, Mfinanga GS, Wandwalo ER, Morkve O. Detection of pulmonary tuberculosis among patients with cough attending outpatient departments in Dar Es Salaam, Tanzania: does duration of cough matter?. BMC Health Serv Res 2009; 9: 112
    CrossrefPubMedGoogle Scholar
  • 32 Lockman S, Hone N, Kenyon TA , et al. Etiology of pulmonary infections in predominantly HIV-infected adults with suspected tuberculosis, Botswana. Int J Tuberc Lung Dis 2003; 7 (8) 714-723
    PubMedGoogle Scholar
  • 33 Daley CL, Small PM, Schecter GF , et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326 (4) 231-235
    CrossrefPubMedGoogle Scholar
  • 34 Daley CL, Mugusi F, Chen LL , et al. Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1996; 154 (1) 105-110
    CrossrefPubMedGoogle Scholar
  • 35 Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007; 11 (12) 1308-1313
    PubMedGoogle Scholar
  • 36 Grant AD, Sidibé K, Domoua K , et al. Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire. Int J Tuberc Lung Dis 1998; 2 (11) 926-934
    PubMedGoogle Scholar
  • 37 Scott JA, Hall AJ, Muyodi C , et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355 (9211) 1225-1230
    CrossrefPubMedGoogle Scholar
  • 38 Gilks CF, Brindle RJ, Otieno LS , et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990; 4 (10) 981-985
    CrossrefPubMedGoogle Scholar
  • 39 Elliott AM, Halwiindi B, Hayes RJ , et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993; 96 (1) 1-11
    PubMedGoogle Scholar
  • 40 Török ME, Yen NT, Chau TT , et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)—associated tuberculous meningitis. Clin Infect Dis 2011; 52 (11) 1374-1383
    CrossrefPubMedGoogle Scholar
  • 41 Arthur G, Nduba VN, Kariuki SM, Kimari J, Bhatt SM, Gilks CF. Trends in bloodstream infections among human immunodeficiency virus-infected adults admitted to a hospital in Nairobi, Kenya, during the last decade. Clin Infect Dis 2001; 33 (2) 248-256
    CrossrefPubMedGoogle Scholar
  • 42 Toossi Z, Mayanja-Kizza H, Hirsch CS , et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123 (2) 233-238
    CrossrefPubMedGoogle Scholar
  • 43 Munsiff SS, Alpert PL, Gourevitch MN, Chang CJ, Klein RS. A prospective study of tuberculosis and HIV disease progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19 (4) 361-366
    CrossrefPubMedGoogle Scholar
  • 44 Cattamanchi A, Ssewenyana I, Davis JL , et al. Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infect Dis 2010; 10: 75
    CrossrefPubMedGoogle Scholar
  • 45 Raby E, Moyo M, Devendra A , et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS ONE 2008; 3 (6) e2489
    CrossrefPubMedGoogle Scholar
  • 46 Markowitz N, Hansen NI, Wilcosky TC , et al; Pulmonary Complications of HIV Infection Study Group. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119 (3) 185-193
    CrossrefPubMedGoogle Scholar
  • 47 Guidelines on the Management of Latent Tuberculosis Infection. Geneva, Switzerland: World Health Organization; 2015
  • 48 American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49 (RR-6): 1-51
    PubMedGoogle Scholar
  • 49 Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K ; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59 (RR-5): 1-25
    PubMedGoogle Scholar
  • 50 Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149 (3) 177-184
    CrossrefPubMedGoogle Scholar
  • 51 Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis . Am J Respir Crit Care Med 2008; 177 (10) 1164-1170
    CrossrefPubMedGoogle Scholar
  • 52 Leung CC, Yam WC, Yew WW , et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med 2010; 182 (6) 834-840
    CrossrefPubMedGoogle Scholar
  • 53 Samandari T, Agizew TB, Nyirenda S , et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9777) 1588-1598
    CrossrefPubMedGoogle Scholar
  • 54 Comstock GW, Baum C, Snider Jr DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119 (5) 827-830
    PubMedGoogle Scholar
  • 55 Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95 (6) 935-943
    PubMedGoogle Scholar
  • 56 Krebs A. The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions. Bull Int Union Tuberc 1976; 51 (1) 193-201
    PubMedGoogle Scholar
  • 57 International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60 (4) 555-564
    PubMedGoogle Scholar
  • 58 Golub JE, Cohn S, Saraceni V , et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015; 60 (4) 639-645
    CrossrefPubMedGoogle Scholar
  • 59 Churchyard GJ, Fielding KL, Lewis JJ , et al; Thibela TB Study Team. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014; 370 (4) 301-310
    CrossrefPubMedGoogle Scholar
  • 60 Martinson NA, Barnes GL, Moulton LH , et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 61 Sterling TR, Villarino ME, Borisov AS , et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365 (23) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 62 Belknap R, Borisov A, Holland D , et al. Adherence to Once-Weekly Self-Administered INH and Rifapentine for Latent TB: iAdhere. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; February 23–26, 2015
    PubMedGoogle Scholar
  • 63 Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170 (4) 445-449
    CrossrefPubMedGoogle Scholar
  • 64 Menzies D, Long R, Trajman A , et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149 (10) 689-697
    CrossrefPubMedGoogle Scholar
  • 65 Chan PC, Yang CH, Chang LY , et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis 2012; 16 (5) 633-638
    PubMedGoogle Scholar
  • 66 Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40 (5) 670-676
    CrossrefPubMedGoogle Scholar
  • 67 Centers for Disease Control and Prevention (CDC). Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50 (15) 289-291
    PubMedGoogle Scholar
  • 68 Centers for Disease Control and Prevention (CDC). Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51 (44) 998-999
    PubMedGoogle Scholar
  • 69 Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (31) 735-739
    PubMedGoogle Scholar
  • 70 Burman W, Benator D, Vernon A , et al; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173 (3) 350-356
    CrossrefPubMedGoogle Scholar
  • 71 Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (2) 93-102
    CrossrefPubMedGoogle Scholar
  • 72 World Health Organization. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis among Adults and Adolescents: Recommendations for HIV-Prevalent and Resource Constrained Settings. Geneva: World Health Organization; 2007
    Google Scholar
  • 73 Hanifa Y, Fielding KL, Charalambous S , et al. Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. Int J Tuberc Lung Dis 2012; 16 (9) 1252-1259
    CrossrefPubMedGoogle Scholar
  • 74 Alamo ST, Kunutsor S, Walley J , et al. Performance of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings: a multisite study in Uganda. Trop Med Int Health 2012; 17 (7) 884-895
    CrossrefPubMedGoogle Scholar
  • 75 Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21 (3) 335-341
    CrossrefPubMedGoogle Scholar
  • 76 Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9 (3) 173-184
    CrossrefPubMedGoogle Scholar
  • 77 Pepper T, Joseph P, Mwenya C , et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis 2008; 12 (4) 397-403
    PubMedGoogle Scholar
  • 78 Pedro-Botet J, Gutiérrez J, Miralles R, Coll J, Rubiés-Prat J. Pulmonary tuberculosis in HIV-infected patients with normal chest radiographs. AIDS 1992; 6 (1) 91-93
    CrossrefPubMedGoogle Scholar
  • 79 Lawn SD, Evans AJ, Sedgwick PM, Acheampong JW. Pulmonary tuberculosis: radiological features in West Africans coinfected with HIV. Br J Radiol 1999; 72 (856) 339-344
    CrossrefPubMedGoogle Scholar
  • 80 Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuber Lung Dis 1995; 76 (6) 518-521
    CrossrefPubMedGoogle Scholar
  • 81 Dawson R, Masuka P, Edwards DJ , et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14 (1) 52-58
    PubMedGoogle Scholar
  • 82 Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369 (9578) 2042-2049
    CrossrefPubMedGoogle Scholar
  • 83 Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18 (2) 384-388
    PubMedGoogle Scholar
  • 84 Monkongdee P, McCarthy KD, Cain KP , et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009; 180 (9) 903-908
    CrossrefPubMedGoogle Scholar
  • 85 Mase SR, Ramsay A, Ng V , et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11 (5) 485-495
    PubMedGoogle Scholar
  • 86 Moore DFGJ, Guzman JA, Mikhail LT. Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test. Diagn Microbiol Infect Dis 2005; 52 (3) 247-254
    CrossrefPubMedGoogle Scholar
  • 87 Guerra RLHN, Hooper NM, Baker JF , et al. Use of the amplified mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest 2007; 132 (3) 946-951
    CrossrefPubMedGoogle Scholar
  • 88 Dinnes J, Deeks J, Kunst H , et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11 (3) 1-196
    PubMedGoogle Scholar
  • 89 Flores LL, Pai M, Colford Jr JM, Riley LW. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol 2005; 5: 55
    CrossrefPubMedGoogle Scholar
  • 90 Theron G, Peter J, van Zyl-Smit R , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184 (1) 132-140
    CrossrefPubMedGoogle Scholar
  • 91 Yoon C, Cattamanchi A, Davis JL , et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS ONE 2012; 7 (11) e48599
    CrossrefPubMedGoogle Scholar
  • 92 Scott LE, McCarthy K, Gous N , et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8 (7) e1001061
    CrossrefPubMedGoogle Scholar
  • 93 Kalokhe AS, Shafiq M, Lee JC , et al. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci 2013; 345 (2) 143-148
    CrossrefPubMedGoogle Scholar
  • 94 Barnard M, Warren R, Gey Van Pittius N , et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186 (12) 1298-1305
    CrossrefPubMedGoogle Scholar
  • 95 Boehme CC, Nabeta P, Hillemann D , et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363 (11) 1005-1015
    CrossrefPubMedGoogle Scholar
  • 96 Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012; 12: 103
    CrossrefPubMedGoogle Scholar
  • 97 Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012; 26 (13) 1635-1643
    CrossrefPubMedGoogle Scholar
  • 98 Blumberg HM, Burman WJ, Chaisson RE , et al; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167 (4) 603-662
    CrossrefPubMedGoogle Scholar
  • 99 Vernon A, Burman W, Benator D, Khan A, Bozeman L ; Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353 (9167) 1843-1847
    CrossrefPubMedGoogle Scholar
  • 100 el-Sadr WM, Perlman DC, Matts JP , et al; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26 (5) 1148-1158
    CrossrefPubMedGoogle Scholar
  • 101 Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE ; National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58 (9) 1308-1311
    CrossrefPubMedGoogle Scholar
  • 102 Perriëns JH, St Louis ME, Mukadi YB , et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332 (12) 779-784
    CrossrefPubMedGoogle Scholar
  • 103 Nahid P, Gonzalez LC, Rudoy I , et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175 (11) 1199-1206
    CrossrefPubMedGoogle Scholar
  • 104 Swaminathan S, Narendran G, Venkatesan P , et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181 (7) 743-751
    CrossrefPubMedGoogle Scholar
  • 105 Blanc FX, Sok T, Laureillard D , et al; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365 (16) 1471-1481
    CrossrefPubMedGoogle Scholar
  • 106 Abdool Karim SS, Naidoo K, Grobler A , et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362 (8) 697-706
    CrossrefPubMedGoogle Scholar
  • 107 Abdool Karim SS, Naidoo K, Grobler A , et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365 (16) 1492-1501
    CrossrefPubMedGoogle Scholar
  • 108 Havlir DV, Kendall MA, Ive P , et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365 (16) 1482-1491
    CrossrefPubMedGoogle Scholar
  • 109 Meintjes G, Lawn SD, Scano F , et al; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8 (8) 516-523
    CrossrefPubMedGoogle Scholar
  • 110 Naidoo K, Yende-Zuma N, Padayatchi N , et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157 (5) 313-324
    CrossrefPubMedGoogle Scholar
  • 111 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M ; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (4) 251-261
    CrossrefPubMedGoogle Scholar
  • 112 Meintjes G, Wilkinson RJ, Morroni C , et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24 (15) 2381-2390
    PubMedGoogle Scholar
  • 113 Hoefsloot W, van Ingen J, Andrejak C , et al; Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42 (6) 1604-1613
    CrossrefPubMedGoogle Scholar
  • 114 Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185 (8) 881-886
    CrossrefPubMedGoogle Scholar
  • 115 Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36 (1) 13-34
    PubMedGoogle Scholar
  • 116 Kaplan JE, Hanson D, Dworkin MS , et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl. 01) S5-S14
    CrossrefPubMedGoogle Scholar
  • 117 Kaplan JE, Masur H, Holmes KK ; USPHS; Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51 (RR-8): 1-52
    PubMedGoogle Scholar
  • 118 Griffith DE, Aksamit T, Brown-Elliott BA , et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 (4) 367-416 (corrected in: Am J Respir Crit Care Med 2007;175(7):7445 [Note: Dosage error in article text])
    CrossrefPubMedGoogle Scholar
  • 119 van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2015; 36 (1) 43-54
    PubMedGoogle Scholar
  • 120 Buhler VB, Pollak A. Human infection with atypical acid-fast organisms; report of two cases with pathologic findings. Am J Clin Pathol 1953; 23 (4) 363-374
    CrossrefPubMedGoogle Scholar
  • 121 Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 2004; 36 (4) 883-889
    CrossrefPubMedGoogle Scholar
  • 122 Bloch KC, Zwerling L, Pletcher MJ , et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129 (9) 698-704
    CrossrefPubMedGoogle Scholar
  • 123 Horsburgh Jr CR, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139 (1) 4-7
    CrossrefPubMedGoogle Scholar
  • 124 Witzig RS, Fazal BA, Mera RM , et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995; 21 (1) 77-85
    CrossrefPubMedGoogle Scholar
  • 125 Santin M, Alcaide F. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2003; 7 (7) 673-677
    PubMedGoogle Scholar
  • 126 Levine B, Chaisson RE. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114 (10) 861-868
    CrossrefPubMedGoogle Scholar
  • 127 Cattamanchi A, Nahid P, Marras TK , et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008; 133 (4) 875-880
    CrossrefPubMedGoogle Scholar
  • 128 Fishman JE, Schwartz DS, Sais GJ. Mycobacterium kansasii pulmonary infection in patients with AIDS: spectrum of chest radiographic findings. Radiology 1997; 204 (1) 171-175
    CrossrefPubMedGoogle Scholar
  • 129 Griffith DE, Brown-Elliott BA, Wallace Jr RJ. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37 (9) 1178-1182
    CrossrefPubMedGoogle Scholar
  • 130 Shitrit D, Peled N, Bishara J , et al. Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. Respir Med 2008; 102 (11) 1598-1603
    CrossrefPubMedGoogle Scholar
  • 131 Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med 2004; 170 (7) 793-798
    CrossrefPubMedGoogle Scholar
  • 132 Schroder KH, Juhlin I. Mycobacterium malmoense sp. nov. Int J Syst Bacteriol 1977; 27: 241-246
    CrossrefPubMedGoogle Scholar
  • 133 Hoefsloot W, van Ingen J, de Lange WC, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009; 34 (4) 926-931
    CrossrefPubMedGoogle Scholar
  • 134 Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010; 10: 612
    CrossrefPubMedGoogle Scholar
  • 135 Henriques B, Hoffner SE, Petrini B, Juhlin I, Wåhlén P, Källenius G. Infection with Mycobacterium malmoense in Sweden: report of 221 cases. Clin Infect Dis 1994; 18 (4) 596-600
    CrossrefPubMedGoogle Scholar
  • 136 Buchholz UT, McNeil MM, Keyes LE, Good RC. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis 1998; 27 (3) 551-558
    CrossrefPubMedGoogle Scholar
  • 137 Claydon EJ, Coker RJ, Harris JR. Mycobacterium malmoense infection in HIV positive patients. J Infect 1991; 23 (2) 191-194
    CrossrefPubMedGoogle Scholar
  • 138 Willocks L, Leen CL, Brettle RP, Rayner A, Harris G, Watt B. Isolation of Mycobacterium malmoense from HIV-positive patients. J Infect 1993; 26 (3) 345-346
    CrossrefPubMedGoogle Scholar
  • 139 Zaugg M, Salfinger M, Opravil M, Lüthy R. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis 1993; 16 (4) 540-549
    CrossrefPubMedGoogle Scholar
  • 140 Fakih M, Chapalamadugu S, Ricart A, Corriere N, Amsterdam D. Mycobacterium malmoense bacteremia in two AIDS patients. J Clin Microbiol 1996; 34 (3) 731-733
    PubMedGoogle Scholar
  • 141 Yoganathan K, Elliott MW, Moxham J, Yates M, Pozniak AL. Pseudotumour of the lung caused by Mycobacterium malmoense infection in an HIV positive patient. Thorax 1994; 49 (2) 179-180
    CrossrefPubMedGoogle Scholar
  • 142 Tortoli E, Piersimoni C, Bartoloni A , et al. Mycobacterium malmoense in Italy: the modern Norman invasion?. Eur J Epidemiol 1997; 13 (3) 341-346
    CrossrefPubMedGoogle Scholar
  • 143 Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56 (3) 167-172
    CrossrefPubMedGoogle Scholar
  • 144 Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63 (7) 627-634
    CrossrefPubMedGoogle Scholar
  • 145 Schwabacher H. A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man. J Hyg (Lond) 1959; 57 (1) 57-67
    CrossrefPubMedGoogle Scholar
  • 146 Eng RH, Forrester C, Smith SM, Sobel H. Mycobacterium xenopi infection in a patient with acquired immunodeficiency syndrome. Chest 1984; 86 (1) 145-147
    CrossrefPubMedGoogle Scholar
  • 147 Tecson-Tumang FT, Bright JL. Mycobacterium xenopi and the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100 (3) 461-462
    PubMedGoogle Scholar
  • 148 Wilks D, George RJ, Spiro SJ. Pulmonary Mycobacterium xenopi infection as a first manifestation of HIV infection. J R Soc Med 1990; 83 (6) 401-402
    PubMedGoogle Scholar
  • 149 Stauffer F, Bankier AA, Strasser G, Kreuzer S, Lahounik E, Rieger A. Mycobacteria other than tuberculosis with an emphasis on Mycobacterium xenopi in clinical specimens from AIDS patients at the University Hospital of Vienna from 1989 to 1996. Wien Klin Wochenschr 1999; 111 (2) 56-58
    PubMedGoogle Scholar
  • 150 van Ingen J, Boeree MJ, de Lange WC , et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14 (3) 385-389
    CrossrefPubMedGoogle Scholar
  • 151 Jacoby HM, Jiva TM, Kaminski DA, Weymouth LA, Portmore AC. Mycobacterium xenopi infection masquerading as pulmonary tuberculosis in two patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20 (5) 1399-1401
    CrossrefPubMedGoogle Scholar
  • 152 Tenholder MF, Moser III RJ, Tellis CJ. Mycobacteria other than tuberculosis. Pulmonary involvement in patients with acquired immunodeficiency syndrome. Arch Intern Med 1988; 148 (4) 953-955
    CrossrefPubMedGoogle Scholar
  • 153 el-Helou P, Rachlis A, Fong I , et al. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. Clin Infect Dis 1997; 25 (2) 206-210
    CrossrefPubMedGoogle Scholar
  • 154 Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis 1992; 15 (1) 161-162
    CrossrefPubMedGoogle Scholar
  • 155 Juffermans NP, Verbon A, Danner SA, Kuijper EJ, Speelman P. Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. AIDS 1998; 12 (13) 1661-1666
    CrossrefPubMedGoogle Scholar
  • 156 Kerbiriou L, Ustianowski A, Johnson MA, Gillespie SH, Miller RF, Lipman MC. Human immunodeficiency virus type 1-related pulmonary Mycobacterium xenopi infection: a need to treat?. Clin Infect Dis 2003; 37 (9) 1250-1254
    CrossrefPubMedGoogle Scholar
  • 157 Gazzola L, Cesari M, Salerno F, Franzetti F, Gori A. Clinical and therapeutic management of pulmonary Mycobacterium xenopi infection in HIV-positive patients. Clin Infect Dis 2004; 38 (11) 1642-1644 , author reply 1644
    CrossrefPubMedGoogle Scholar
  • 158 Bankier AA, Stauffer F, Fleischmann D , et al. Radiographic findings in patients with acquired immunodeficiency syndrome, pulmonary infection, and microbiologic evidence of Mycobacterium xenopi . J Thorac Imaging 1998; 13 (4) 282-288
    CrossrefPubMedGoogle Scholar
  • 159 Viterbo V, Midiri M, Stellacci G , et al. [Acquired immunodeficiency syndrome and pulmonary Mycobacterium xenopi infection. Role of computerized tomography]. Radiol Med (Torino) 2000; 99 (6) 443-448
    PubMedGoogle Scholar
  • 160 Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother 2013; 68 (3) 659-665
    CrossrefPubMedGoogle Scholar
  • 161 Andréjak C, Lescure FX, Pukenyte E , et al; Xenopi Group. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64 (4) 291-296
    CrossrefPubMedGoogle Scholar
  • 162 Dooley KE, Sayre P, Borland J , et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62 (1) 21-27
    CrossrefPubMedGoogle Scholar